ArticleBlood2019

JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms.

Tata Nageswara Rao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.